CD8A and graft versus host disease: In summary, although deletion of NFAT in all CD3+/CD90.1+ T cells may be superior in protecting allo-HCT recipients, NFAT ablation in CD8+ T cells only reduced the risk for severe GvHD while allowing MCMV control.